NASDAQ : VYNE
VYNE Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 28.56 USD (At close: Jul 27, 2026) · Market cap 19.05M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 19.05M |
| Enterprise Value | -5.88M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 667,057 |
| Shares Outstanding | 667,057 |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 2.00% |
| Owned by Institutions (%) | 36.97% |
| Float | 613,691 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.96 |
| Forward PS | 31.75 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 20.86 |
| Quick Ratio | 20.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -63.16% |
| Return on Assets (ROA) | -37.01% |
| Return on Invested Capital (ROIC) | -44.25% |
| Return on Capital Employed (ROCE) | -199.67% |
| Weighted Average Cost of Capital (WACC) | 15.28% |
| Revenue Per Employee | $45,400 |
| Profits Per Employee | -$2.15M |
| Employee Count | 10 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 4,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -60.88% |
| 50-Day Moving Average | 34.07 |
| 200-Day Moving Average | 28.15 |
| Relative Strength Index (RSI) | 39.73 |
| Average Volume (20 Days) | 44,265 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 183,974 |
| Short Previous Month | 104,336 |
| Short % of Shares Out | 27.58% |
| Short % of Float | 29.98% |
| Short Ratio (days to cover) | 0.15 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 454,000 |
| Gross Profit | 454,000 |
| Operating Income | -24.37M |
| Pretax Income | -21.71M |
| Net Income | -21.46M |
| EBITDA | -49.17M |
| EBIT | -49.19M |
| Loss Per Share | -$25.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 24.93M |
| Total Debt | n/a |
| Net Cash | 24.93M |
| Net Cash Per Share | $37.37 |
| Equity (Book Value) | 24.64M |
| Book Value Per Share | 36.93 |
| Working Capital | 24.55M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.74M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 23,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.74M |
| FCF Per Share | -$38.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -5,367.40% |
| Pretax Margin | -4,782.82% |
| Profit Margin | n/a |
| EBITDA Margin | -10,830.18% |
| EBIT Margin | -10,835.24% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.42% |
| Shareholder Yield | -0.42% |
| Earnings Yield | -112.63% |
| FCF Yield | -135.13% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $100.00 |
| Price Target Difference | 250.14% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -35.33 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |